Interestingly, it has been observed that genistein, a TFEB activator (Arguello et al., 2021), has beneficial effects on NAFLD (Xin et al., 2019), once again suggesting that TFEB activation helps treat the disease. This evidence concerns the gene TFEB and metabolic dysfunction-associated steatotic liver disease.